MCM
XGN icon

Massar Capital Management’s Exagen XGN Stock Holding History

Massar Capital Management’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-140,000
Closed -$420K – 397
2026
Q1 		$420K Sell
140,000
-30,000
-18% -$116K 0.05% 171
2025
Q4 		$1.03M Hold
170,000
– – 0.11% 138
2025
Q3 		$1.87M Hold
170,000
– – 0.25% 53
2025
Q2 		$1.19M Buy
170,000
+149,160
+716% +$907K 0.89% 28
2025
Q1 		$74.8K Buy
+20,840
New +$78.7K 0.08% 104

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Massar Capital Management's XGN Position: Q2 2026 in Review

Massar Capital Management sold out of Exagen (XGN) in Q2 2026, closing a stake of 140,000 shares — an estimated $420K sold.

Massar Capital Management first reported a position in XGN in Q1 2025 and held it in 5 quarters. The position peaked at $1.87M in Q3 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Massar Capital Management reported no remaining Exagen position as of Q2 2026 after selling out during the quarter.
  • Massar Capital Management sold 140,000 Exagen shares in Q2 2026, an estimated $420K.
  • Massar Capital Management first reported a position in Exagen in Q1 2025 and held it in 5 quarters.
  • Massar Capital Management's Exagen position peaked at $1.87M in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Massar Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.